Homepage - Axsome Therapeutics
Jan 31, 2025 · Axsome is developing innovative treatments including AXS-05, AXS-12, and AXS‑14. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia. Please see full Prescribing Information, including Boxed Warning, and the Medication Guide.
Axsome Therapeutics Announces Settlement Agreement …
1 day ago · NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...
Axsome Therapeutics Resolves Generic Patent Litigation With …
1 day ago · In January, Axsome Therapeutics reported preliminary Auvelity net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and full year of 2024 ...
Axsome bounces back as FDA clears depression drug
5 days ago · Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared...
FDA finally blesses Axsome’s rapid-acting migraine drug Symbravo
Jan 31, 2025 · Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo.
After trial win, Axsome eyes FDA filing for narcolepsy hopeful
Nov 27, 2024 · Axsome now plans to move “expeditiously” toward an FDA filing, but it will first request a pre-new drug application meeting with the agency, the executive added.
Axsome Therapeutics Announces FDA Approval of AUVELITY™,
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Announces Settlement Agreement
1 day ago · “Axsome is proud of its commitment to innovating treatments aimed at improving the lives of the millions of patients living with central nervous system disorders.
Why Axsome Therapeutics Stock Is Skyrocketing Today
2 days ago · Axsome resolved litigation with a rival pharmaceutical company, protecting one of Axsome's key drugs. The settlement protects Axsome's revenue stream for more than a decade. Axsome, maker of the ...
Axsome secures top drug’s future with Teva patent settlement
2 days ago · Dive Brief: Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent settlement with Teva Pharmaceuticals that will keep a generic copy of Axsome’s top drug at bay in the U.S. until at least 2038.; Axsome had sued Teva for patent infringement when the generic drugmaker filed for approval of a …